Key Insights

Highlights

Treatment Research

6 treatments under study, led by Bemarituzumab Trifluridinetipiracil

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06680622Phase 2Active Not Recruiting

Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Showing all 1 trials

Research Network

Common Treatments

  • Bemarituzumab Trifluridinetipiracil1
  • Paclitaxel1
  • Bemarituzumab Paclitaxel Ramucirumab1
  • Bemarituzumab Irinotecan1
  • Ramucirumab1

Active Sponsors

  • Amgen1
  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1
  • Technical University of Munich1
  • Johannes Gutenberg University Mainz1

Top Investigators

Related Conditions

  • Metastatic Gastroesophageal Adenocarcinoma1

Activity Timeline